0.9827
price down icon3.66%   -0.0373
pre-market  Pre-market:  .93   -0.0527   -5.36%
loading
Alzamend Neuro Inc stock is traded at $0.9827, with a volume of 106.27K. It is down -3.66% in the last 24 hours and up +35.54% over the past month. Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
106.27K
Relative Volume:
0.30
Market Cap:
$6.48M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.1469
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
-7.29%
1M Performance:
+35.54%
6M Performance:
-40.80%
1Y Performance:
-89.08%
1-Day Range:
Value
$0.94
$1.05
1-Week Range:
Value
$0.94
$1.05
52-Week Range:
Value
$0.6427
$15.06

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name
Name
Alzamend Neuro Inc
Name
Phone
844-722-6333
Name
Address
3500 LENOX RD. NE, ATLANTA
Name
Employee
7
Name
Twitter
Name
Next Earnings Date
2024-09-12
Name
Latest SEC Filings
Name
ALZN's Discussions on Twitter

Compare ALZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALZN
Alzamend Neuro Inc
0.9827 6.48M 0 -5.85M -8.00M -6.6877
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-01-21 Initiated Ascendiant Capital Markets Buy

Alzamend Neuro Inc Stock (ALZN) Latest News

pulisher
Mar 30, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025
pulisher
Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com

Mar 24, 2025
pulisher
Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK

Mar 20, 2025
pulisher
Mar 20, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 19, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan

Mar 18, 2025
pulisher
Mar 17, 2025

Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 15, 2025

Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com

Mar 14, 2025
pulisher
Mar 13, 2025

Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace

Mar 11, 2025
pulisher
Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga

Mar 11, 2025
pulisher
Mar 10, 2025

Alzamend Neuro Inc. (ALZN) reports earnings - Quartz

Mar 10, 2025
pulisher
Mar 05, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro announces initiation date of Phase II trial of AL001 - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Announces Phase II Clinical Study of AL001 for Bipolar Disorder Expected to Start in Q3 2025 - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Alzamend Neuro Plans Phase II Trial for Advanced Lithium Treatment in Bipolar Disorder | ALZN Stock News - StockTitan

Mar 04, 2025
pulisher
Mar 03, 2025

Alzamend Neuro Announces Bylaws Amendment and New Stock Series By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Alzamend Neuro Announces Bylaws Amendment and New Stock Series - Investing.com

Mar 03, 2025
pulisher
Mar 01, 2025

Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Alzamend Neuro inks deal for equity securities sale - Investing.com

Feb 28, 2025

Alzamend Neuro Inc Stock (ALZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):